Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D12AIV
|
|||
| Drug Name |
PRGN-3005
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Refractory hematologic malignancy [ICD-11: 2A85.5; ICD-10: C83.1] | Phase 1 | [1] | |
| Company |
Precigen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ovarian carcinoma antigen CA125 (MUC16) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03907527) Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Precigen. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.